Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
STRO-002
SUTRO BIOPHARMA, INC.
Ovarian Cancer
2 trials -
STRO-004
SUTRO BIOPHARMA, INC.
Head and Neck Squamous Cell Carcinoma HNSCC
1 trial -
SXC-2023
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Use Disorder
1 trial -
SYN115
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Dependence
1 trial -
SafeMedWaste
BRIGHT MINDS BIOSCIENCES INC.
Opioid Use Disorder
1 trial -
Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteers
BioNTech SE
Tuberculosis
1 trial -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects
Arbutus Biopharma Corp
Chronic hepatitis B virus Infection
1 trial -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults.
NEUROCRINE BIOSCIENCES INC
Movement disorders
1 trial -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults
NEUROCRINE BIOSCIENCES INC
Neurological and neuropsychiatric conditions
1 trial -
Saline
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Addiction
1 trial -
Salmeterol
BRIGHT MINDS BIOSCIENCES INC.
Healthy
1 trial -
Sativex(Registered Trademark)
BRIGHT MINDS BIOSCIENCES INC.
Cannabis
1 trial -
Satraplatin in combo with vinorelbine
BRIGHT MINDS BIOSCIENCES INC.
Advanced Solid Tumors
1 trial -
Semaglutide Extended-release for Injectable Suspension, 1 mg
BRIGHT MINDS BIOSCIENCES INC.
Diabetes Mellitus, Type 2
1 trial -
Single Ascending Dose of SAB-176
SAB Biotherapeutics
PHA1A
1 trial -
Single Dose Pharmacokinetics and Relative Bioavailability of Sayana Press via Upper Arm Injection Relative to Anterior Thigh and Abdomen
Pfizer Australia Pty Ltd
long-term female contraception
1 trial -
Single dose oral bioequivalence study of Cladribine 10 mg Tablets and Mavenclad® 10 mg tablets (Cladribine) in healthy adult human subjects under fed conditions
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers.
1 trial -
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the comparative bioavailability of Test Product Dapagliflozin/metformin hydrochloride 5 mg/1000 mg film-coated tablets to Reference Product Xigduo 5 mg/1000 mg film-coated tablets in healthy adult male and female subjects under fed conditions.
Laboratorios Tillomed Spain S.L.U
Bioavailability study in healthy volunteers under fed conditions.
1 trial -
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition
1 trial -
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.
Laboratorios Tillomed Spain S.L.U
Bioavailability study in healthy volunteers under fasting conditions.
1 trial -
Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.
The George Institute
No medical condition.
1 trial -
Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.
Pari Pharma GmbH
Comparative bioequivalence study in healthy volunteers under fasting conditions.
1 trial -
Sonelokimab
MoonLake Immunotherapeutics
Relative Bioequivalence
1 trial -
Sotrovimab
Vir Biotechnology
COVID-19 Infection
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources